World's Best Scientists 2026 revealed!
Michele Baccarani

Michele Baccarani

Award Badge
Medicine
Italy
2023

D-Index & Metrics

Medicine

D-Index
133
Citations
89694
World Ranking
2182
National Ranking
44

Research.com Recognitions

  • 2023 - Research.com Medicine in Italy Leader Award

Overview

Michele Baccarani is affiliated with the University of Bologna in Italy and has an extensive research record in the field of medicine, with a primary focus on hematology. Their work spans multiple subfields, including genetics, rheumatology, public health, environmental and occupational health, and oncology.

Their research largely centers on hematologic malignancies, particularly chronic myeloid leukemia (CML) and related leukemias. The main topics covered in their publications include chronic myeloid leukemia treatments, chronic lymphocytic leukemia research, eosinophilic disorders and syndromes, acute lymphoblastic leukemia research, acute myeloid leukemia research, HER2/EGFR in cancer research, and lymphoma diagnosis and treatment.

Frequent publication venues for Michele Baccarani include journals specializing in hematology and oncology such as Leukemia, Blood, Clinical Lymphoma Myeloma & Leukemia, Frontiers in Oncology, and Blood Advances.

Some recent papers authored or coauthored by Michele Baccarani are:

  • The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia (2020, Leukemia)
  • High-risk additional chromosomal abnormalities at low blast counts herald death by CML (2020, Leukemia)
  • INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia (2021, Blood Advances)
  • Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives (2020, Journal of Clinical Medicine)
  • BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS (2020, Leukemia)

Throughout their career, Michele Baccarani has collaborated frequently with a consistent group of coauthors, including Fausto Castagnetti, Gianantonio Rosti, Simona Soverini, Massimiliano Bonifacio, and Francesco Albano.

Best Publications

  • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

    Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

    Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot

  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus

  • Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

    Hagop Kantarjian;Neil P. Shah;Andreas Hochhaus;Jorge Cortes

  • Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

    Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus

  • Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

    Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser

  • Prognostic discrimination in "good-risk" chronic granulocytic leukemia

    JE Sokal;EB Cox;M Baccarani;S Tura

  • Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

    Moshe Talpaz;Richard T. Silver;Brian J. Druker;John M. Goldman

  • A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre

  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    Andreas Hochhaus;Michele Baccarani;Richard T. Silver;Charles A. Schiffer

  • Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

    Andreas Hochhaus;Richard A. Larson;François Guilhot;Jerald P. Radich

  • Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

    Michele Cavo;Paola Tacchetti;Francesca Patriarca;Maria Teresa Petrucci

  • Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

    Timothy P Hughes;Michael W Deininger;Andreas Hochhaus;Susan Branford

  • A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

    Joerg Hasford;Markus Pfirrmann;Rüdiger Hehlmann;Norman C. Allan

  • Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

    Jorge E. Cortes;Giuseppe Saglio;Hagop M. Kantarjian;Michele Baccarani

  • Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

    Andreas Hochhaus;Hagop M. Kantarjian;Michele Baccarani;Jeffrey H. Lipton

  • Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

    Hagop M. Kantarjian;Neil P. Shah;Jorge E. Cortes;Michele Baccarani

  • Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients.

    S A Pileri;S Ascani;M C Cox;C Campidelli

  • Chronic myeloid leukaemia

    Rüdiger Hehlmann;Andreas Hochhaus;Michele Baccarani

Frequent Co-Authors

Giovanni Martinelli
Giovanni Martinelli University of Bologna
Giuseppe Saglio
Giuseppe Saglio University of Turin
Michele Cavo
Michele Cavo University of Bologna
Sante Tura
Sante Tura University of Bologna
Jorge E. Cortes
Jorge E. Cortes Augusta University
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Pier Luigi Zinzani
Pier Luigi Zinzani University of Bologna
Timothy P. Hughes
Timothy P. Hughes South Australian Health and Medical Research Institute
Francois Guilhot
Francois Guilhot Grenoble Alpes University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Looking to explore alternate healthcare roles or accelerate your career? There are several flexible online degrees and fast-track programs that can help you get started or advance in the medical field, even if you don’t plan to pursue a traditional MD.

For registered nurses aiming for top leadership roles, a dnp program without clinical hours may offer an expedited route to doctoral-level credentials. Aspiring practical nurses can consider lpn online programs that provide a fast, flexible entry point into healthcare.

Nurses seeking specialized mental health training may benefit from the msn to pmhnp online pathway, enabling advanced practice in psychiatric and mental health nursing. Prefer the administrative side? A bachelors in health administration provides business and management skills for leadership in clinics, hospitals, and health organizations.

Each of these online options allows you to balance education with work and personal commitments, paving multiple career pathways in America's diverse healthcare system.

Best Scientists Citing Michele Baccarani

Trending Scientists